IVMED-85
Pediatric Myopia
Phase 1Active (IND open, trial initiating)
Key Facts
Indication
Pediatric Myopia
Phase
Phase 1
Status
Active (IND open, trial initiating)
Company
About iVeena Delivery Systems
iVeena Delivery Systems is a clinical-stage biotech company pioneering pharmacologic treatments for refractive eye diseases, with a focus on keratoconus and pediatric myopia. The company has achieved key milestones, including an Orphan Drug Designation for IVMED-80 and an open IND for IVMED-85, supported by recent Series B-2 financing. Led by a team with deep expertise in ophthalmology and drug delivery, iVeena is advancing its first-in-class eyedrop formulations into clinical trials to address significant unmet needs in ocular health.
View full company profile